Molecular approaches to personalizing management of ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Cytoreductive surgery and chemotherapy improve ovarian cancer survival but not cure rates.
• Late diagnosis and drug-resistant dormant cancer cells contribute to poor outcomes.
• Ovarian cancer heterogeneity necessitates distinct therapeutic and diagnostic approaches for different subtypes.

Purpose of the Study:

• To outline strategies for personalized ovarian cancer therapy and early detection.
• To highlight molecular targets for low-grade and high-grade serous ovarian cancers.
• To explore methods for overcoming chemotherapy resistance and targeting dormant cells.

Main Methods:

• Review of molecular, cellular, and clinical biology of ovarian cancer.
• Identification of actionable molecular targets (e.g., Ras/Raf, PI3K, BRCA).
• Discussion of multi-pathway inhibition and cell cycle modulation strategies.

Main Results:

• Low-grade cancers can be targeted via Ras/Raf mutations.
• High-grade cancers present opportunities for targeting PI3K (PI3Kness) and BRCA inactivation (BRCAness).
• Paclitaxel and platinum sensitivity can be modulated by targeting cell cycle regulators.

Conclusions:

• Personalized therapy integrating conventional and targeted agents is essential.
• Targeting dormant cell survival mechanisms (autophagy, cytokines, growth factors) is critical.
• Personalized, two-stage screening using serum biomarkers and imaging can improve early detection.